IN-VITRO COMPARATIVE EVALUATION OF BRANDED AND GENERIC FUROSEMIDE40MG TABLET.
- Published in:
- Advances in Pharmacology & Toxicology, 2024, v. 24, n. 2, p. 69
- By:
- Publication type:
- Article
Works matching DE "PHARMACEUTICAL industry
Results: 5000
1
2
NKure and CRISPR Partners to Develop Of-the-Shelf CAR T Therapy in India.
- Published in:
- Indian Practitioner, 2025, v. 78, n. 5, p. 41
- Publication type:
- Article
3
J&J MedTech, Qure.ai Partner for Early Lung Cancer Detection.
- Published in:
- Indian Practitioner, 2025, v. 78, n. 5, p. 40
- Publication type:
- Article
4
EMA approved orphan medicines since the implementation of the orphan legislation.
- Published in:
- Orphanet Journal of Rare Diseases, 2025, v. 20, n. 1, p. 1, doi. 10.1186/s13023-025-03756-7
- By:
- Publication type:
- Article
5
Advances in the biosynthesis of tetraacetyl phytosphingosine, a key substrate of ceramides.
- Published in:
- Synthetic & Systems Biotechnology, 2025, v. 10, n. 1, p. 1, doi. 10.1016/j.synbio.2024.07.005
- By:
- Publication type:
- Article
6
Determination of Chlorpheniramine Maleate in its Pharmaceutical Preparations Using Homemade Turbidity Flow Injection Analyzer.
- Published in:
- Baghdad Science Journal, 2025, v. 22, n. 5, p. 1451, doi. 10.21123/bsj.2024.10244
- By:
- Publication type:
- Article
7
Chemical Composition of the Leaf Essential Oil of Tritaxis glabella and Its Free-Radical Scavenging Activity.
- Published in:
- Chemistry of Natural Compounds, 2025, v. 61, n. 3, p. 603, doi. 10.1007/s10600-025-04716-0
- By:
- Publication type:
- Article
8
Green Supply Chain Integration and Sustainable Performance in Pharmaceutical Industry of China: A Moderated Mediation Model.
- Published in:
- Systems, 2025, v. 13, n. 5, p. 388, doi. 10.3390/systems13050388
- By:
- Publication type:
- Article
9
Deciphering the Risk–Return Dynamics of Pharmaceutical Companies Using the GARCH-M Model.
- Published in:
- Risks, 2025, v. 13, n. 5, p. 87, doi. 10.3390/risks13050087
- By:
- Publication type:
- Article
10
Marine-Derived Compounds Combined with Nanoparticles: A Focus on the Biomedical and Pharmaceutical Sector.
- Published in:
- Marine Drugs, 2025, v. 23, n. 5, p. 207, doi. 10.3390/md23050207
- By:
- Publication type:
- Article
11
LETTERS.
- Published in:
- Pulse International, 2025, v. 26, n. 10, p. N.PAG
- By:
- Publication type:
- Article
12
Need for life cycle assessment of pharmaceuticals for kidney healthcare.
- Published in:
- Clinical & Experimental Nephrology, 2025, v. 29, n. 6, p. 702, doi. 10.1007/s10157-025-02647-2
- By:
- Publication type:
- Article
13
Development and Validation of a Sensitive LC-MS/MS Method for the Determination of N-Nitroso-Atenolol in Atenolol-Based Pharmaceuticals.
- Published in:
- Separations (2297-8739), 2025, v. 12, n. 5, p. 122, doi. 10.3390/separations12050122
- By:
- Publication type:
- Article
14
IW-Studie: „Hemmschuh für Pharmastandort Deutschland".
- Published in:
- Pharma + Food, 2025, n. 2, p. 10
- Publication type:
- Article
15
Interview mit Dr. Olaf Weinmann zum Cyber Resilience Act.
- Published in:
- Pharma + Food, 2025, n. 2, p. 24
- Publication type:
- Article
16
CEOs von Novartis und Sanofi : „Wir hoffen, dass Europa die Gunst der Stunde nutzt.".
- Published in:
- Pharma + Food, 2025, n. 2, p. 8
- Publication type:
- Article
17
Heimische Märkte wieder mehr im Fokus.
- Published in:
- Pharma + Food, 2025, n. 2, p. 6
- Publication type:
- Article
18
Top 5 Beiträge.
- Published in:
- Pharma + Food, 2025, n. 2, p. 8
- Publication type:
- Article
19
Körber verbindet globale Standards mit lokaler ExpertiseNahtlose Sekundärverpackungs-Lösungen weltweit.
- Published in:
- Pharma + Food, 2025, n. 2, p. 22
- Publication type:
- Article
20
Rezeptursoftware macht Pharmaproduktion sicherer und effizienter.
- Published in:
- Pharma + Food, 2025, n. 2, p. 60
- Publication type:
- Article
21
Effizient statt überlastet.
- Published in:
- Pharma + Food, 2025, n. 2, p. 64
- Publication type:
- Article
22
Optimising Cancer Medicine in Clinical Practices: Are Neoadjuvant and Adjuvant Immunotherapies Affordable for Cancer Patients in Low- and Middle-Income Countries?
- Published in:
- Cancers, 2025, v. 17, n. 10, p. 1722, doi. 10.3390/cancers17101722
- By:
- Publication type:
- Article
23
Responsibility of the pharmaceutical industry: Sustainability and communication with publics.
- Published in:
- Catalan Journal of Communication & Cultural Studies, 2025, v. 17, n. 1, p. 61, doi. 10.1386/cjcs_00104_1
- By:
- Publication type:
- Article
24
The advisory body on animal ethics of a global pharmaceutical company: A global organization to address ethical and societal concerns about animal use.
- Published in:
- Laboratory Animals, 2025, v. 59, n. 3, p. 390, doi. 10.1177/00236772241302537
- By:
- Publication type:
- Article
25
PRODUCTS & SERVICES.
- Published in:
- 2025
- Publication type:
- Product Review
26
Unlocking access: a comprehensive analysis of medicines accessibility for rare diseases in Thailand.
- Published in:
- Orphanet Journal of Rare Diseases, 2025, v. 20, n. 1, p. 1, doi. 10.1186/s13023-025-03754-9
- By:
- Publication type:
- Article
27
A facile, scalable, and sustainable approach to the preparation of the indole-core of alectinib.
- Published in:
- Bulletin of the Chemical Society of Japan, 2025, v. 98, n. 3, p. 1, doi. 10.1093/bulcsj/uoaf019
- By:
- Publication type:
- Article
28
ANÁLISE DO IMPACTO DA IMPLEMENTAÇÃO DO LEAN SIX SIGMA NA INDÚSTRIA FARMACÊUTICA: UM ESTUDO DE REVISÃO SISTEMÁTICA.
- Published in:
- Revista Fatec Zona Sul (REFAS), 2025, v. 11, n. 4, p. 1, doi. 10.26853/Refas_ISSN-2359-182X_v11n04_05
- By:
- Publication type:
- Article
29
Notizen aus der Wirtschaft.
- Published in:
- Nachrichten aus der Chemie, 2025, v. 73, n. 6, p. 24, doi. 10.1002/nadc.20254151548
- By:
- Publication type:
- Article
30
Announcements.
- Published in:
- Oncology (08909091), 2009, v. 23, n. 7, p. 571
- Publication type:
- Article
31
Announcements.
- Published in:
- Oncology (08909091), 2008, v. 22, n. 14, p. 1634
- Publication type:
- Article
32
Small Steps Forward in the Land of Small Tumors.
- Published in:
- Oncology (08909091), 2008, v. 22, n. 14, p. 1623
- By:
- Publication type:
- Article
33
New Formulation of BLP25 Liposome Vaccine: Phase II Study Interim Results.
- Published in:
- Oncology (08909091), 2005, v. 19, n. 13, p. 1682
- Publication type:
- Article
34
Announcements.
- Published in:
- Oncology (08909091), 2005, v. 19, n. 9, p. 1117
- Publication type:
- Article
35
What's in the Pipeline?
- Published in:
- RT: The Journal for Respiratory Care Practitioners, 2011, v. 24, n. 7, p. 29
- Publication type:
- Article
36
Conflict-Free?
- Published in:
- 2009
- By:
- Publication type:
- Editorial
37
Dividend policy issues in the European pharmaceutical industry: new empirical evidence.
- Published in:
- European Journal of Health Economics, 2023, v. 24, n. 5, p. 803, doi. 10.1007/s10198-022-01510-5
- By:
- Publication type:
- Article
38
How Managed Entry Agreements can improve allocation in the public health system: a mechanism design approach.
- Published in:
- European Journal of Health Economics, 2021, v. 22, n. 5, p. 699, doi. 10.1007/s10198-021-01284-2
- By:
- Publication type:
- Article
39
Efficiency ratio and rocketing drug prices: old concerns and new possibilities.
- Published in:
- 2020
- By:
- Publication type:
- Editorial
40
International impact of external reference pricing: should national policy-makers care?
- Published in:
- 2019
- By:
- Publication type:
- journal article
41
Conflict of interest disclosure: striking a balance?
- Published in:
- 2019
- By:
- Publication type:
- Editorial
42
Pharmaceutical pricing conundrum: time to get rid of it?
- Published in:
- 2018
- By:
- Publication type:
- Editorial
43
A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK.
- Published in:
- 2018
- By:
- Publication type:
- journal article
44
A methodological framework for assessing agreement between cost-effectiveness outcomes estimated using alternative sources of data on treatment costs and effects for trial-based economic evaluations.
- Published in:
- 2018
- By:
- Publication type:
- journal article
45
Healthcare utilization and costs in primary care patients with dementia: baseline results of the DelpHi-trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
46
Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy.
- Published in:
- 2018
- By:
- Publication type:
- journal article
47
Corruption costs lives: evidence from a cross-country study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
48
Competition in pharmaceuticals: more product- than price-oriented?
- Published in:
- 2018
- By:
- Publication type:
- Editorial
49
Why trash don't pass? pharmaceutical licensing and safety performance of drugs.
- Published in:
- 2017
- By:
- Publication type:
- journal article
50
Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data.
- Published in:
- 2017
- By:
- Publication type:
- journal article